One of the most commonly prescribed growth hormone peptides. It's a copy of the first 29 amino acids of your body's natural growth hormone-releasing hormone, so it triggers your pituitary to release GH in natural pulses -- the way your body is supposed to do it.
What to Expect
Week 1–2
Improved sleep quality, particularly deep sleep phases. Mild increase in morning energy. GH pulses beginning to normalize.
Week 3–6
Better recovery from exercise. Subtle fat loss and improved muscle tone. Improved skin hydration and elasticity. Enhanced sense of well-being.
Week 8+
Significant body composition improvements. Joint and connective tissue health enhanced. Normalized GH/IGF-1 axis. Sustained sleep and recovery benefits.
Common Side Effects
Scientific Overview
Sermorelin is a synthetic 29-amino acid analog corresponding to the first 29 residues of native GHRH (GHRH 1-29). It stimulates pituitary somatotrophs via the GHRH receptor to produce physiological GH secretion patterns. FDA-approved for pediatric growth hormone deficiency, sermorelin maintains normal GH pulsatility and does not suppress endogenous GHRH production. Clinical studies demonstrate improvements in body composition, sleep quality (increased slow-wave sleep), and IGF-1 normalization with sustained treatment.
Dosing
200-300 mcg subq before bed, daily. Give it 3-6 months for best results.
Practical Guide
Reconstitution
Mix 3mg or 9mg vial with 1-3mL BAC water per physician instructions.
Storage
Refrigerate after reconstitution. Use within 30 days.
Injection Sites
Subcutaneous with insulin syringe. Rotate injection sites. 29-31g needle.
Timing
Inject 30 minutes before bed on empty stomach. This synergizes with natural nocturnal GH pulse.
Food
Inject on empty stomach for optimal GH release. No food for 30 minutes after injection.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer
- ✕Pituitary tumors
- ✕Pregnancy/nursing
- ✕Obesity-related hypothalamic dysfunction (reduced efficacy)
Drug Interactions
Recommended Monitoring
- →IGF-1 levels every 3-6 months
- →Fasting glucose periodically
- →Thyroid function (GH affects T4 to T3 conversion)
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
A novel approach for the treatment of AML, through GHRH antagonism: MIA-602.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
New agonist- and antagonist-based treatment approaches for advanced prostate cancer.
PEGylation of growth hormone-releasing hormone (GRF) analogues.
When the light turns blue.
Growth hormone releasing hormone.
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.